Development of the cardioprotective drugs class based on pathophysiology of myocardial infarction: A comprehensive review

Curr Probl Cardiol. 2024 May;49(5):102480. doi: 10.1016/j.cpcardiol.2024.102480. Epub 2024 Feb 21.

Abstract

The cardiovascular system is mainly responsible for the transport of substances necessary to cellular metabolism. However, for the good performance of this function, there is need for adequate control of blood pressure levels of tissue perfusion and systemic arterial. Acute myocardial infarction is one of the complications of the cardiovascular system, that most affects the population around the world. This condition can be defined as a disease generated by an imbalance of oxygen concentrations used in cardiovascular metabolism, this change usually occurs because coronary occlusion, which prevents myocardial blood flow. The diagnosis is based on the set of clinical and laboratory investigations, which are in the release of cardiac enzyme biomarkers, cardiovascular and hemodynamic changes and cardiac accommodations. The treatment consists in the use of concomitant cardiovascular drugs, such as: antihypertensive, antiplatelet and hypolipidemic. Despite improvements in clinical and pharmacological management, acute myocardial infarction remains the leading cause of death worldwide. This finding encourages the scientific research of new drugs for the treatment of myocardial infarction or supporting therapies aimed at reducing the levels of deaths and comorbities generated by cardiovascular diseases.

Keywords: Cardioprotection; Cardiovascular therapy.

Publication types

  • Review

MeSH terms

  • Antihypertensive Agents / therapeutic use
  • Blood Pressure
  • Hemodynamics
  • Humans
  • Myocardial Infarction* / drug therapy
  • Myocardial Infarction* / epidemiology

Substances

  • Antihypertensive Agents